About SolasCure
SolasCure is a company based in Cardiff (United Kingdom) founded in 2017. SolasCure has raised $34.12 million across 4 funding rounds from investors including Brain Biotech, Development Bank of Wales and Eva Pharma. The company has 11 employees as of July 31, 2021. SolasCure offers products and services including Aurase Wound Gel. SolasCure operates in a competitive market with competitors including BioMonde, EZ Debride, XSONX and Regenerative Wound Therapies, among others.
- Headquarter Cardiff, United Kingdom
- Employees 11 as on 31 Jul, 2021
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Solascure Limited
- Date of Incorporation 20 Jun, 2017
- Jurisdiction CAMBRIDGE, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$34.12 M (USD)
in 4 rounds
-
Latest Funding Round
$514.76 K (USD), Grant
Mar 20, 2024
-
Investors
Brain Biotech
& 9 more
-
Employee Count
11
as on Jul 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of SolasCure
SolasCure offers a comprehensive portfolio of products and services, including Aurase Wound Gel.
Enzymatic gel for debriding chronic wounds and promoting healing.
People of SolasCure
Unlock access to complete
Funding Insights of SolasCure
SolasCure has successfully raised a total of $34.12M across 4 strategic funding rounds. The most recent funding activity was a Grant round of $514.76 thousand completed in March 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in SolasCure
SolasCure has secured backing from 10 investors, including institutional, angel, and venture fund investors. Prominent investors backing the company include Brain Biotech, Development Bank of Wales and Eva Pharma.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Provider of equity funding and business & property development loans
|
Locked | Locked | Locked |
Investor details for SolasCure
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by SolasCure
Investment portfolio details for SolasCure
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - SolasCure
Detailed financials for SolasCure
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Solascure Comparisons
Peer comparison for SolasCure
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of SolasCure
SolasCure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as BioMonde, EZ Debride, XSONX and Regenerative Wound Therapies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Larva therapy is manufactured for debridement of non-healing wounds.
|
|
| Locked | Locked | Locked |
A patent-pending wound debridement tool is developed by EZ Debride.
|
|
| Locked | Locked | Locked |
Develops wound hygiene systems using micro-vibrational technology to enhance healing.
|
|
| Locked | Locked | Locked |
Offers advanced wound management through innovative medical devices for healthcare.
|
Detailed competitors of SolasCure
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Solascure
Complete news archive for SolasCure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about SolasCure
SolasCure was founded in 2017 and raised its 1st funding round 4 years after it was founded.
SolasCure is headquartered in Cardiff, United Kingdom. It is registered at Cardiff, Wales, United Kingdom.
SolasCure is a funded company, having raised a total of $34.12M across 4 funding rounds to date.
As of Jul 31, 2021, the latest employee count at SolasCure is 11.
SolasCure was founded in 2017 in Cardiff, United Kingdom. Products for wound care are developed within the medical biotechnology sector. Operations center on innovative hydrogels for debridement and healing. The primary product, Aurase, incorporates an active enzyme that has been isolated and cloned from medical maggots traditionally used for wound cleaning. Focus remains on clinical applications for chronic and acute wounds.
SolasCure's top competitors include BioMonde, EZ Debride and XSONX.
SolasCure offers Aurase Wound Gel.
SolasCure has 10 investors. Key investors include Brain Biotech, Development Bank of Wales, Eva Pharma, Seneca Partners, and Jonathan Milner.